| 摘要 |
Utilization of heparin cofactor II in preventing and treating diseases caused by the abnormal acceleration of the functions of macrophages, pulmonary epithelial cells and/or synovial cells, in particular, blood coagulation promoting effect and cytokine producing effect (for example, articular diseases, lung diseases, diseases in association with vascular failure); and utilization of heparin cofactor II in producing preventives/remedies for the above diseases. The preventives/remedies containing heparin cofactor II can be topically administered to a joint, the respiratory tract, around a vascular failure, etc. and achieve a therapeutic effect at the target site in a low HCII dose.
|
